Dyspepsia. Helicobacter pylori [H.pylori] as the cause of diseases classified
Conditions
Interventions
Intervention 1: Intervention group received standard treatment of anti H pylori which include Amoxicillin 500 mg four times daily, Bismuth citrate 120 mg four times daily, Omeprazole 20 mg twice dai
Treatment - Drugs
Intervention group received standard treatment of anti H pylori which include Amoxicillin 500 mg four times daily, Bismuth citrate 120 mg four times daily, Omeprazole 20 mg twice daily, Clarithromyc
Control group received standard treatment of anti H pylori which include Amoxicillin 500 mg four times daily, Bismuth citrate 120 mg four times daily, Omeprazole 20 mg twice daily, Clarithromycin 500
Sponsors
Vice chancellor for research, Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
17 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria included: All patients with gastrointestinal symptoms and dyspepsia which refer to the Gastroenterology Clinics of Al-Zahra hospital, Noor, Poursina Hakim Research Center and Ardakan hospital for endoscopy by a gastroenterologist recruited with full consent if Helicobacter pylori tests were positive (confirmed by histology, Rapid urease test or stool antigen test). Exclusion criteria included: Patients previously received eradication of Helicobacter pylori treatment? Presence of underlying disease such as cirrhosis? Renal failure? Severe cardiac disease? malignancy outside of the GI? Age less than 17 and more than 80? Simultaneous use of NSAIDs? Concomitant use of steroids? Recent gastrointestinal bleeding? pregnancy or lactation.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication. Timepoint: Prior to and one month after intervention. Method of measurement: Stool antigen. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug side effects. Timepoint: During and after drug consumption. Method of measurement: Visiting and call-chek list.;Drug tolerance. Timepoint: During drug consumption. Method of measurement: Visiting and call. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mehdi Zobeiri
Kermanshah University of Medical Sciences
Outcome results
None listed